CN1220501C - Eye drop of double rhizoma coptidis - Google Patents
Eye drop of double rhizoma coptidis Download PDFInfo
- Publication number
- CN1220501C CN1220501C CN 02117620 CN02117620A CN1220501C CN 1220501 C CN1220501 C CN 1220501C CN 02117620 CN02117620 CN 02117620 CN 02117620 A CN02117620 A CN 02117620A CN 1220501 C CN1220501 C CN 1220501C
- Authority
- CN
- China
- Prior art keywords
- add
- minutes
- ethanol
- water
- stir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 8
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011780 sodium chloride Substances 0.000 claims abstract description 8
- 208000036142 Viral infection Diseases 0.000 claims abstract description 5
- 230000009385 viral infection Effects 0.000 claims abstract description 5
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 3
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 3
- 229960003321 baicalin Drugs 0.000 claims abstract description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 3
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 3
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 3
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 3
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000009413 insulation Methods 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 7
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 7
- 238000002386 leaching Methods 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000003518 caustics Substances 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 241000205585 Aquilegia canadensis Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 241000218202 Coptis Species 0.000 abstract 3
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 230000001976 improved effect Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000005030 aluminium foil Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to double coptis eye drop, which can be applied to the treatment of ophthalmological viral infection. The double coptis eye drop is composed of two parts: double coptis aseptic powder and eye drop solvent. The medicine components referred in the present invention are made into the eye drop to apply to the treatment of ophthalmological diseases for the first time. The biological availability of the medicine components is improved, and therapeutic effect and medication safety are strengthened. The effective medicine components are baicalin and chlorogenic acid, and the solvent is isoosmotic solution composed of sodium chloride and ethylparaben.
Description
Affiliated technical field
The middle pharmaceutically active ingredient---SHUANGHUANLIAN---that the present invention relates to is made eye drop first, is applied to the treatment of ophthalmology viral infection, is intended to improve the bioavailability of effective ingredient, increases curative effect and drug safety.
Background technology
At traditional tcm field, before the applicating history of SHUANGHUANLIAN can be traced back to the centuries; In modern age, SHUANGHUANLIAN is first Chinese medicinal formulae of making injectable powder; Its excellent therapeutic effect is extensively confirmed and is approved.But in the application of SHUANGHUANLIAN, following defective is arranged simultaneously: the degeneration of the easy moisture absorption caking of (1), SHUANGHUANLIAN medicated powder influences curative effect and the bioavailability and the drug safety of medicine, so that lose therapeutical effect.(2), apparent therapeutic effect is slow.(3), substep is inhomogeneous in the medicine body, during the ophthalmology illness treatment, adopts injection or oral administration mode, its topical therapeutic DeGrain.Consider from the pharmacokinetics aspect, when ophthalmology illness is treated, injection (comprising quiet notes) and oral administration mode, drug absorption enters behind the blood with blood circulation to the whole body substep, also must see through blood-eye barrier, could arrive the site of action of eye focus, and medicine is circulation time in vivo, also can cause structural change in various degree owing to modes such as oxidation, reduction, decomposition, combinations, finally reaching lesions position, to show bioavailability lower; Adopt the mode that strengthens dosage for reaching comparatively ideal therapeutic effect, the hidden danger of drug safety is then arranged.
Summary of the invention
The present invention makes eye drop with SHUANGHUANLIAN by the method for double pack first, has not only solved the rotten problem of SHUANGHUANLIAN moisture absorption caking, and, solved the unfavorable problem of whole body drug treatment effect.
The medicine eye drop of double rhizoma coptidis that is applied to the ophthalmology treatment of viral infections of the present invention is characterized in that being the double pack form, is made up of with solvent two parts SHUANGHUANLIAN aseptic powder and eye drip respectively, and wherein the SHUANGHUANLIAN aseptic powder contains Flos Lonicerae [with chlorogenic acid (C
16H
18O
9) meter] be 14.0-25.0 milligram/gram; Contain Radix Scutellariae [with baicalin (C
21H
18O
11) meter] be 220.0-292.0 milligram/gram; The eye drip solvent is the aqueous solution that sodium chloride and ethyl hydroxybenzoate are made into, wherein sodium chloride-containing 9.0 mg/ml, contain ethyl hydroxybenzoate 0.5 mg/ml.
The technical solution adopted for the present invention to solve the technical problems is:
One, extract to concentrate the SHUANGHUANLIAN effective ingredient of back preparation, behind low temperature sterilization, cold drying is prepared into sterilized powder, is sub-packed in the plastic bottle that dry heat sterilization and cold wind dry up, and adds a cover the bottle cap of liner sealing gasket, is first moisture preventive measure; The moistureproof aluminium foil bag of outer plastic packaging is second moisture preventive measure.Among the above-mentioned preparation technology, its core technology is: (1) cold drying prepares aseptic fine powder, the dried packing plastic bottle of (2) dry heat sterilization cold wind, the moistureproof bottle cap of (3) sealing gasket, the moistureproof aluminium foil bag of (4) plastic packaging.
Two, medicine and solvent are packed the preparation eye drop respectively, and in ophthalmic remedy, if treat the eye virus infectious disease in the mode of oral or other whole body administrations with SHUANGHUANLIAN, not only dosage is big, and medicine is difficult to pass through blood-eye barrier with the SHUANGHUANLIAN first Application.Make eye drop, topical, amount of application is few, has increased curative effect and drug safety.Among the above-mentioned preparation technology, its core technology is: SHUANGHUANLIAN effective ingredient and eye drip solvent are packed respectively, have guaranteed the stability of effective ingredient.
Three, the useful result of this product is: when solving SHUANGHUANLIAN powder moisture absorption problem, adopt the method for two dose packages to prepare eye drop, when having demonstrated fully the treatment ophthalmology illness, adopt bioavailability height that the local application administering mode of direct eye drip embodied, reduce use amount, increase the advantageous feature of curative effect and drug safety.And, reduce the financial burden that use amount has also reduced the patient.
Embodiment
Eye drop of double rhizoma coptidis
[prescription] Fructus Forsythiae 100g
Flos Lonicerae 50g
Radix Scutellariae 50g
—————————————————
Make 200
Eye drip solvent sodium chloride 9.0g
Ethyl hydroxybenzoate 0.5g
——————————————————
Make 1000ml
[method for making] gets Radix Scutellariae, decocts with water each 1 hour of secondary (8,6 times of amounts), merging filtrate, and filtrate uses 2mol/L hydrochloric acid solution adjust pH to 1.0-2.0.80 ℃ of insulations 30 minutes, left standstill 24 hours, filter, precipitation adds 8 times of amounts of water, stir, with 40% sodium hydroxide solution adjust pH to 6.0-7.0, add equivalent ethanol, stir and make dissolving, filter, filtrate transfers pH to 2.0 in 80 ℃ of insulations 30 minutes with the 2mol/L hydrochloric acid solution, left standstill 12 hours, and filtered, precipitation is washed till pH value to 4.0 with ethanol, add 10 times of amounts of water, stir, to 6.0-7.0, add 0.5% active carbon with 40% sodium hydroxide solution adjust pH, fully stir, 50 ℃ of insulations 30 minutes add after 1-2 doubly measures ethanol and stir, and filter immediately, filtrate is used 2mol/L hydrochloric acid solution adjust pH to 2.0, in 80 ℃ of insulations 30 minutes, left standstill 12 hours, filter, after precipitation is washed with small amount of ethanol, in dry below 60 ℃.
Flos Lonicerae, Fructus Forsythiae extract: Flos Lonicerae, Fructus Forsythiae adds 10 times in water respectively, 8 times of amounts, dipping is after 30 minutes earlier, decoct secondary, each 1 hour, merging filtrate, be concentrated into the clear paste of relative density 1.20-1.25 (70 ℃), be chilled to 40 ℃ and slowly add ethanol, make to contain alcohol amount and reach 75%, fully stir, left standstill 12 hours, the leaching supernatant reclaims ethanol to there not being the alcohol flavor, adds water 3-4 and doubly measures, left standstill 12 hours, the leaching supernatant, being concentrated into relative density is the clear paste of 1.10-1.15 (80 ℃), is chilled to 40 ℃, add ethanol, make the alcohol amount of containing reach 85% and leave standstill more than 12 hours, the leaching supernatant reclaims ethanol to there not being the alcohol flavor.
Get Radix Scutellariae extract, add suitable quantity of water, heating and with 40% caustic lye of soda adjust pH to 7.0 makes dissolving, add above-mentioned Flos Lonicerae, Fructus Forsythiae extract, add water to 200ml, add 0.5% active carbon, keep pH7.0, heat little boiling 15 minutes, cooling filters, and adds to the full amount of water for injection, in 115 ℃ of sterilizations 30 minutes, in 1 week of cold preservation, filter with microporous filter membrane, filtrate concentrates, and lyophilization is distributed into 200, every 60mg tightly seals, promptly.
The preparation of eye drip solvent adds water 1000ml with sodium chloride and ethyl hydroxybenzoate, stirs to make it dissolving, filters with microporous filter membrane, sterilizes 30 minutes for 115 ℃, and cooling is distributed into 200, promptly.
Creativeness of the present invention realizes by clinical, toxicology and pharmacology data, provides in the lump during examination as to substances.
Fig. 1 is an eye drop of double rhizoma coptidis preparation technology flow chart.
Claims (2)
1. a medicine eye drop of double rhizoma coptidis that is applied to the ophthalmology treatment of viral infections is characterized in that being the double pack form, is made up of with solvent two parts SHUANGHUANLIAN aseptic powder and eye drip respectively, and wherein the SHUANGHUANLIAN aseptic powder contains Flos Lonicerae [with chlorogenic acid (C
16H
8O
9) meter] be 14.0-25.0 milligram/gram; Contain Radix Scutellariae [with baicalin (C
21H
18O
11) meter] be 220.0-292.0 milligram/gram; The eye drip solvent is the aqueous solution that sodium chloride and ethyl hydroxybenzoate are made into, wherein sodium chloride-containing 9.0 mg/ml, contain ethyl hydroxybenzoate 0.5 mg/ml.
2. according to the described eye drop of double rhizoma coptidis of claim 1, it is characterized in that SHUANGHUANLIAN aseptic powder wherein prepares by following method: at first get Radix Scutellariae 50 grams, decoct with water secondary, each 1 hour, merging filtrate, filtrate use 2mol/L hydrochloric acid solution adjust pH to 1.0-2.0; 80 ℃ of insulations 30 minutes, left standstill 24 hours, filter, precipitation adds 8 times of amounts of water, stir, with 40% sodium hydroxide solution adjust pH to 6.0-7.0, add equivalent ethanol, stir and make dissolving, filter, filtrate transfers pH to 2.0 in 80 ℃ of insulations 30 minutes with the 2mol/L hydrochloric acid solution, left standstill 12 hours, and filtered, precipitation is washed till pH value to 4.0 with ethanol, add 10 times of amounts of water, stir, to 6.0-7.0, add 0.5% active carbon with 40% sodium hydroxide solution adjust pH, fully stir, 50 ℃ of insulations 30 minutes add after 1-2 doubly measures ethanol and stir, and filter immediately, filtrate is used 2mol/L hydrochloric acid solution adjust pH to 2.0, in 80 ℃ of insulations 30 minutes, left standstill 12 hours, filter, after precipitation is washed with small amount of ethanol, in dry below 60 ℃; Secondly extracting honeysuckle 50 restrains, Fructus Forsythiae 100 grams add 10 times in water respectively, 8 times of amounts, dipping is after 30 minutes earlier, decoct secondary, each 1 hour, merging filtrate, be concentrated into the clear paste of relative density 1.20-1.25, be chilled to 40 ℃ and slowly add ethanol, make to contain alcohol amount and reach 75%, fully stir, left standstill 12 hours, the leaching supernatant reclaims ethanol to there not being the alcohol flavor, adds water 3-4 and doubly measures, left standstill 12 hours, the leaching supernatant is concentrated into the clear paste that relative density is 1.10-1.15, is chilled to 40 ℃, add ethanol, make the alcohol amount of containing reach 85% and leave standstill more than 12 hours, the leaching supernatant reclaims ethanol to there not being the alcohol flavor; Get Radix Scutellariae extract once more, add entry, the heating and with 40% caustic lye of soda adjust pH to 7.0, make dissolving, add above-mentioned Flos Lonicerae, Fructus Forsythiae extract, add water to 200ml, add 0.5% active carbon, keep pH7.0, heat little boiling 15 minutes, cooling, filter, add to the full amount of water for injection, in 115 ℃ of sterilizations 30 minutes, 1 week of cold preservation filters with microporous filter membrane, and filtrate concentrates, lyophilization is distributed into 200, every 60mg; Wherein the eye drip solvent prepares by following method: sodium chloride 9.0 gram and ethyl hydroxybenzoate 0.5 gram are added water 1000ml, stir and make it dissolving, filter with microporous filter membrane, 115 ℃ of sterilizations 30 minutes are cooled off, and are distributed into 200, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02117620 CN1220501C (en) | 2002-05-10 | 2002-05-10 | Eye drop of double rhizoma coptidis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02117620 CN1220501C (en) | 2002-05-10 | 2002-05-10 | Eye drop of double rhizoma coptidis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456186A CN1456186A (en) | 2003-11-19 |
| CN1220501C true CN1220501C (en) | 2005-09-28 |
Family
ID=29410325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02117620 Expired - Lifetime CN1220501C (en) | 2002-05-10 | 2002-05-10 | Eye drop of double rhizoma coptidis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1220501C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109350683A (en) * | 2018-10-15 | 2019-02-19 | 吴迪 | A kind of eyedrops and preparation method thereof can be relieved the swelling and pain of eyes red heat |
| CN115569160A (en) * | 2022-10-08 | 2023-01-06 | 沈阳兴齐眼药股份有限公司 | Shuanghuanglian eye drops and its preparation method, stability improvement method and extract extraction method |
-
2002
- 2002-05-10 CN CN 02117620 patent/CN1220501C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1456186A (en) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| US11439681B2 (en) | Traditional Chinese medicine composition for treating type 2 diabetes | |
| CN105381159B (en) | It is a kind of for treat burn compound aloe barbadensis Miller polysaccharide external-use gel | |
| CN1220501C (en) | Eye drop of double rhizoma coptidis | |
| CN1067577C (en) | Preparation of isotomic Shengmei injecta | |
| CN100336534C (en) | Medicine for treating coronary heart disease and its preparation method | |
| CN1698835A (en) | Compound Chinese medicinal injection for treating cardiovascular and cerebrovascular diseases | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN115487268A (en) | A composition for promoting blood circulation and toxin metabolism, and its preparation method | |
| CN107773695A (en) | A kind of Chinese medicine for being used to treat flat wart | |
| CN108524448B (en) | A kind of euphadienol anti-cataract eye-drops preparations and its preparation method and application | |
| CN101961394A (en) | Traditional Chinese medicine for treating tumors | |
| CN111419970A (en) | Traditional Chinese medicine composition for treating myocarditis | |
| CN1053817C (en) | Acanthopanax root injection freeze-dried powder injection and producing technology for acanthopanax root extract | |
| CN105998431A (en) | Traditional Chinese medicine composition for treating cataract and preparation method thereof | |
| CN115429836B (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN101732637A (en) | Chinese medicament for treating cardiovascular and cerebrovascular diseases | |
| CN1398626A (en) | Yinhuang powder injection for intravenous injection and its prepn process | |
| CN110538230A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing infectious endocarditis | |
| CN100431532C (en) | Breviscapine and borneol constituted composite injection formulation and preparation method thereof | |
| CN1062447C (en) | "Zhenmi" eye drops | |
| CN101884660A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN1954879A (en) | Granule of zhamusa-four-does and its preparation method | |
| CN1857305A (en) | Pile-treating Fanteng preparation and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenyang Sinqi Pharmaceutical Co., Ltd. Assignor: Liu Jidong Contract fulfillment period: 2005.10.26 to 2010.10.26 Contract record no.: 2008210000060 Denomination of invention: Eye drop of double rhizoma coptidis Granted publication date: 20050928 License type: Exclusive license Record date: 20081106 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2005.10.26 TO 2010.10.26; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081106 |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG XINGQI MEDICINE CO., LTD. Free format text: FORMER OWNER: LIU JIDONG Effective date: 20111013 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111013 Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027, Liaoning, Shenyang economic and Technological Development Zone, No. three, 12, No. 4, Shenyang Xing Qi Pharmaceutical Co., Ltd. Patentee before: Liu Jidong |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 110024, 4, 12, three street, Shenyang economic and Technological Development Zone Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: Shenyang Sinqi Pharmaceutical Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050928 |
|
| CX01 | Expiry of patent term |